Anemia

High-Dose vs Low-Dose IV Iron Dosing Regimens Compared

Publish Date November 20, 2020

Ferric carboxymaltose can be safely administered at doses of 500 mg in hemodialysis patients, according to a new study.

Risk for Ophthalmic Problems Not Higher With HIF-PHI Use

Publish Date November 19, 2020

Investigators analyzed retinal hemorrhages and macular edema events in patients treated with roxadustat or darbepoetin alfa.

Adverse Event Rates Higher in the Early Post-RBC Transfusion Period

Publish Date November 18, 2020

Red blood cell transfusions can treat anemia over the short term but may increase the risk for adverse events, particularly those associated with blood volume, according to investigators.

Roxadustat Effective for Renal Anemia Regardless of Inflammation Status

Publish Date November 17, 2020

In both dialysis and nondialysis trials, no increases in roxadustat dose were needed for inflamed patients.

Roxadustat Does Not Increase Risk of Major Cardiovascular Events

Publish Date October 27, 2020

In pooled analyses, researchers found no higher rates of major adverse cardiovascular events with roxadustat treatment among patients with anemia of dialysis- or nondialysis-dependent chronic kidney disease.

Roxadustat, ESA Similarly Effective in Nondialysis CKD

Publish Date October 27, 2020

At 18-24 weeks, average hemoglobin levels in the roxadustat group was within target range.

Anemia Treatments Underused in Non-Dialysis CKD

Publish Date October 26, 2020

In the prospective CKD-DOPPS study, only 40% for patients with hemoglobin less than 10 g/dL initiated anemia medication.

Minimal Interference Found Between Phosphate Binders, Daprodustat

Publish Date October 26, 2020

In a study, hemoglobin values did not differ meaningfully among daprodustat users, whether or not they also took one or more phosphate binders.

HIF-PHIs Show Short-Term Efficacy and Safety

Publish Date September 23, 2020

A current meta-analysis of HIF-PHIs showed that these drugs improve the response rate of hemoglobin and decrease hepcidin levels.

Factors Contributing to Darbepoetin Responsiveness in CKD

Publish Date September 22, 2020

In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy.